![](/static/253f0d9/assets/icons/icon-96x96.png)
![](https://lemmy.world/pictrs/image/db7182d9-181a-45e1-b0aa-6768f144911a.jpeg)
You’re right, and an upvote for you. I’ve seen colleagues who encounter a 90% drop in efficacy when making the leap to Phase 1 trials (and this is excluding safety concerns!).
It is rigorous and thank everything the Process is put in place. But I specifically used Oxycontin as an example for a pertinent reason. Rigour isn’t applied to everyone equally, and I think that itself underscores a need to think critically.
Excuse me, I see a fellow IDM enjoyer. Any recommendations for me?